Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused ​tumors to disappear or shrink in an early-stage ‌trial.

Reuters • Oct 24, 2026

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer

BEERSE, BELGIUM , Oct. 24, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus hormone therapy (androgen deprivation therapy), given for six months before and after surgery, with radical prostatectomy alone in patients with high-risk localised or locally advanced prostate cancer.1 The apalutamide plus hormone therapy regimen reduced the risk of disease recurrence or death by 62% compared with surgery alone.1 The regimen also showed a nominal improvement in metastasis-free survival (MFS), with a 51% lower risk of metastasis or death.1 Patients receiving perioperative treatment also experienced longer time to subsequent therapy compared with surgery alone.1

GlobeNewsWire • a day ago

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer

New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgery Twice as many patients remained free from subsequent treatment at three years with perioperative apalutamide plus ADT compared with surgery alone Results evaluated outcomes versus surgery alone, building on the primary results presented at ASCO 2026 NEW BRUNSWICK, N.J., Oct. 24, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given for six months before and after surgery, with radical prostatectomy alone in patients with high-risk localized or locally advanced prostate cancer.

PRNewsWire • a day ago

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Amgen focuses on high-growth areas including oncology, inflammation, and rare diseases to drive its clinical pipeline. Johnson & Johnson offers a diversified business model split between innovative medicine and global medical technology.

The Motley Fool • 20 hours ago

UK approves J&J's oral psoriasis pill

Britain's medicines regulator on Friday approved Johnson & Johnson's daily pill for adults and ​teenagers with moderate-to-severe plaque psoriasis, a ‌skin condition causing red, scaly and often itchy or painful patches.

Reuters • Oct 23, 2026

J&J Stock Reclaims 50-Day SMA: Is it Time to Buy, Sell or Hold?

J&J stock reclaims its 50-day SMA, but falling earnings estimates, a premium valuation and MedTech weakness raise questions about its near-term outlook.

Zacks Investment Research • Oct 23, 2026

JNJ Stock Has a New Growth Story, but One Business Needs to Catch Up

Johnson and Johnson just posted a quarter where one business charged ahead while another quietly stalled, and which side wins out will determine whether the stock earns its premium valuation over rivals like Merck and AbbVie.

24/7 Wall Street • Oct 22, 2026

Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026

IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson reports first real-world VARIPULSE Pro Platform data and 12-Month OMNYPULSE Platform outcomes for atrial fibrillation treatment.

Business Wire • Oct 22, 2026

Procter & Gamble Jumps 6% as Earnings Beat Draws Defensive Buyers; Johnson & Johnson Rises 3%, Coca-Cola Ticks Up

Defensive consumer and healthcare stocks are drawing fresh money. As large-caps generally fall, Procter & Gamble‘s (NYSE:PG | PG Price Prediction) quarterly beat is catching the interest of today's buyers.

24/7 Wall Street • Oct 22, 2026

Social Security Isn't Enough: 5 Secure Dividend Stocks to Fund Your Retirement

A 3.3% Social Security bump leaves most retirees short, but five blue-chip dividend payers across four sectors have quietly built the kind of growing income stream that picks up where the government leaves off.

24/7 Wall Street • Oct 22, 2026